<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">VzWkrVBmSNZXKsdwYybWM3p</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000600009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600609</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000047</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Complica&#231;&#245;es microvasculares e disfun&#231;&#227;o auton&#244;mica card&#237;aca em pacientes com diabete melito tipo 1</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Fernando K</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gross</surname>
            <given-names>Jorge L</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodrigues</surname>
            <given-names>Ticiana C</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date date-type="collection" publication-format="electronic">
        <month>06</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>6</issue>
      <fpage>484</fpage>
      <lpage>489</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>23</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>01</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A presen&#231;a de neuropatia auton&#244;mica card&#237;aca (NAC) em pacientes com diabete melito (DM) est&#225; associada a aumento da mortalidade e a complica&#231;&#245;es cr&#244;nicas microvasculares do diabete. OBJETIVO: Investigar uma poss&#237;vel associa&#231;&#227;o entre achados sugestivos de NAC durante a realiza&#231;&#227;o do teste ergom&#233;trico (TE) e nefropatia e retinopatia em pacientes com DM tipo 1. M&#201;TODOS: Realizamos um estudo transversal com 84 pacientes com DM tipo 1. Todos os pacientes foram submetidos &#224; avalia&#231;&#227;o cl&#237;nica e laboratorial e realizaram TE, sendo que aqueles que apresentaram achados sugestivos de isquemia mioc&#225;rdica foram exclu&#237;dos da an&#225;lise dos dados (n = 3). A avalia&#231;&#227;o de complica&#231;&#245;es microvasculares (retinopatia e nefropatia) foi realizada na amostra. RESULTADOS: Os pacientes com nefropatia e aqueles com retinopatia atingiram uma frequ&#234;ncia card&#237;aca (FC) durante o pico de exerc&#237;cio (FC m&#225;xima) menor e apresentaram aumento menor da FC em rela&#231;&#227;o ao repouso (&#916;FC pico) quando comparados com aqueles sem estas complica&#231;&#245;es. Esses pacientes tamb&#233;m apresentaram menor redu&#231;&#227;o da FC no segundo e 4&#186; minutos ap&#243;s o final do teste (&#916;FC recupera&#231;&#227;o dois e 4 minutos). Ap&#243;s realiza&#231;&#227;o de an&#225;lise multivariada com controle para os poss&#237;veis fatores de confus&#227;o, os &#916;FC recupera&#231;&#227;o em dois e 4 minutos, FC m&#225;xima e o &#916;FC pico permaneceram significativamente associados &#224; retinopatia; e os &#916;FC recupera&#231;&#227;o no segundo e 4&#186; minutos permaneceram associados &#224; presen&#231;a de nefropatia. CONCLUS&#195;O: O TE pode ser considerado um instrumento adicional para a detec&#231;&#227;o precoce de NAC e para identificar pacientes em maior risco para complica&#231;&#245;es microvasculares do diabete.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Diabetes mellitus tipo 1</kwd>
        <kwd>neuropatias diab&#233;ticas</kwd>
        <kwd>angiopatias diab&#233;ticas</kwd>
        <kwd>teste de esfor&#231;o</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>15</day>
        <month>04</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Complica&#231;&#245;es microvasculares e disfun&#231;&#227;o auton&#244;mica card&#237;aca em pacientes com diabete melito tipo 1</bold>
    </p>
    <p>
      <bold>Fernando K. Almeida; Jorge L. Gross; Ticiana C. Rodrigues</bold>
    </p>
    <p><sup>I</sup>Servi&#231;o de Endocrinologia do Hospital de Cl&#237;nicas de Porto Alegre </p>
    <p><sup>II</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="endb">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A presen&#231;a de neuropatia auton&#244;mica card&#237;aca (NAC) em pacientes com diabete melito (DM) est&#225; associada a aumento da mortalidade e a complica&#231;&#245;es cr&#244;nicas microvasculares do diabete. </p>
    <p><bold>OBJETIVO:</bold> Investigar uma poss&#237;vel associa&#231;&#227;o entre achados sugestivos de NAC durante a realiza&#231;&#227;o do teste ergom&#233;trico (TE) e nefropatia e retinopatia em pacientes com DM tipo 1. </p>
    <p><bold>M&#201;TODOS:</bold> Realizamos um estudo transversal com 84 pacientes com DM tipo 1. Todos os pacientes foram submetidos &#224; avalia&#231;&#227;o cl&#237;nica e laboratorial e realizaram TE, sendo que aqueles que apresentaram achados sugestivos de isquemia mioc&#225;rdica foram exclu&#237;dos da an&#225;lise dos dados (n = 3). A avalia&#231;&#227;o de complica&#231;&#245;es microvasculares (retinopatia e nefropatia) foi realizada na amostra. </p>
    <p><bold>RESULTADOS:</bold> Os pacientes com nefropatia e aqueles com retinopatia atingiram uma frequ&#234;ncia card&#237;aca (FC) durante o pico de exerc&#237;cio (FC m&#225;xima) menor e apresentaram aumento menor da FC em rela&#231;&#227;o ao repouso (&#916;FC pico) quando comparados com aqueles sem estas complica&#231;&#245;es. Esses pacientes tamb&#233;m apresentaram menor redu&#231;&#227;o da FC no segundo e 4&#186; minutos ap&#243;s o final do teste (&#916;FC recupera&#231;&#227;o dois e 4 minutos). Ap&#243;s realiza&#231;&#227;o de an&#225;lise multivariada com controle para os poss&#237;veis fatores de confus&#227;o, os &#916;FC recupera&#231;&#227;o em dois e 4 minutos, FC m&#225;xima e o &#916;FC pico permaneceram significativamente associados &#224; retinopatia; e os &#916;FC recupera&#231;&#227;o no segundo e 4&#186; minutos permaneceram associados &#224; presen&#231;a de nefropatia. </p>
    <p><bold>CONCLUS&#195;O:</bold> O TE pode ser considerado um instrumento adicional para a detec&#231;&#227;o precoce de NAC e para identificar pacientes em maior risco para complica&#231;&#245;es microvasculares do diabete. </p>
    <p><bold>Palavras-chave:</bold> Diabetes mellitus tipo 1/complica&#231;&#245;es, neuropatias diab&#233;ticas, angiopatias diab&#233;ticas, teste de esfor&#231;o. </p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A neuropatia auton&#244;mica &#233; uma complica&#231;&#227;o cr&#244;nica decorrente da presen&#231;a do diabete melito (DM) e est&#225; associada a um controle glic&#234;mico inadequado<sup>1-3</sup>. Entretanto, apesar de sua elevada preval&#234;ncia e do significativo impacto que seus sintomas acarretam sobre a qualidade de vida dos indiv&#237;duos afetados, ela continua sendo subdiagnosticada. A grande variedade de manifesta&#231;&#245;es cl&#237;nicas e a complexidade dos m&#233;todos de avalia&#231;&#227;o contribuem para a pouca identifica&#231;&#227;o da neuropatia auton&#244;mica. Adicionalmente, j&#225; foi demonstrado que a sua presen&#231;a eleva o risco de eventos cardiovasculares e a mortalidade nos pacientes com DM<sup>3,4</sup>. A neuropatia auton&#244;mica card&#237;aca (NAC) possui uma estreita associa&#231;&#227;o com mortalidade de origem cardiovascular<sup>4,5</sup> e, mais recentemente, as evid&#234;ncias t&#234;m indicado uma associa&#231;&#227;o entre NAC e complica&#231;&#245;es microvasculares, possivelmente relacionadas a uma altera&#231;&#227;o do controle vasomotor dos pequenos vasos<sup>6</sup>. Em rela&#231;&#227;o a NAC, h&#225; diversos m&#233;todos de avalia&#231;&#227;o bem validados, muitos deles dispon&#237;veis no consult&#243;rio, como a resposta auton&#244;mica ao ortostatismo postural, a manobra de Valsalva e a varia&#231;&#227;o da frequ&#234;ncia card&#237;aca (FC) durante os ciclos de inspira&#231;&#227;o profunda<sup>4</sup>. </p>
    <p>Entre as manifesta&#231;&#245;es t&#237;picas de neuropatia auton&#244;mica, destacam-se: perda da percep&#231;&#227;o de hipoglicemias, altera&#231;&#245;es gastrointestinais (diarreia, constipa&#231;&#227;o, incontin&#234;ncia fecal e gastroparesia), altera&#231;&#245;es urin&#225;rias (bexiga neurog&#234;nica, manifestada tanto por incontin&#234;ncia quanto por reten&#231;&#227;o urin&#225;ria), disfun&#231;&#245;es sexuais, altera&#231;&#245;es das gl&#226;ndulas sudor&#237;paras (pele seca) e cardiovasculares. As altera&#231;&#245;es auton&#244;micas cardiovasculares refletem-se mais precocemente em uma redu&#231;&#227;o da variabilidade da FC, fen&#244;meno que predisp&#245;e a hipotens&#227;o postural, intoler&#226;ncia ao exerc&#237;cio e instabilidade cardiovascular transoperat&#243;ria, al&#233;m de taquicardia em repouso<sup>4</sup>. H&#225; concomitantemente uma menor redu&#231;&#227;o nos n&#237;veis da press&#227;o arterial diast&#243;lica noturna, fen&#244;meno que tamb&#233;m poderia estar implicado no desenvolvimento de les&#245;es de &#243;rg&#227;os-alvo<sup>7,8</sup>. A frequ&#234;ncia de NAC aumenta com a idade e com o tempo de dura&#231;&#227;o do diabete, e sua presen&#231;a associa-se a retinopatia, nefropatia e neuropatia perif&#233;rica<sup>3,4,9,10</sup>. H&#225; concomitantemente uma menor redu&#231;&#227;o nos n&#237;veis da press&#227;o arterial diast&#243;lica noturna, fen&#244;meno que tamb&#233;m poderia estar implicado no desenvolvimento de les&#245;es de &#243;rg&#227;os-alvo<sup>7,8</sup>. A frequ&#234;ncia de NAC aumenta com a idade e com o tempo de dura&#231;&#227;o do diabete, e sua presen&#231;a associa-se a retinopatia, nefropatia e neuropatia perif&#233;rica<sup>3,4,9,10</sup>. </p>
    <p>Em pacientes com DM tipo 1 (DM1), as altera&#231;&#245;es auton&#244;micas card&#237;acas, avaliadas pelo &#237;ndice da FC na inspira&#231;&#227;o/expira&#231;&#227;o e pela resposta card&#237;aca durante a indu&#231;&#227;o de ortostatismo, relacionaram-se ao desenvolvimento de nefropatia diab&#233;tica (ND) ao longo dos anos<sup>11</sup>. Tamb&#233;m j&#225; foi demonstrado que dist&#250;rbios auton&#244;micos detectados por pupilometria aumentam o risco de doen&#231;a renal futura<sup>12</sup>. Pacientes com nefropatia e varia&#231;&#227;o anormal da FC durante o ciclo de inspira&#231;&#227;o/expira&#231;&#227;o apresentam um risco de eventos cardiovasculares fatal e n&#227;o fatal maior do que aqueles com apenas nefropatia e sem os dist&#250;rbios auton&#244;micos<sup>13</sup>. </p>
    <p>A varia&#231;&#227;o da FC em rela&#231;&#227;o ao pico do exerc&#237;cio e aos primeiros minutos de recupera&#231;&#227;o ap&#243;s teste ergom&#233;trico (TE) j&#225; foi validada como fator progn&#243;stico cardiovascular<sup>14,15</sup>. Entretanto, a associa&#231;&#227;o desse marcador de disfun&#231;&#227;o auton&#244;mica card&#237;aca com complica&#231;&#245;es renais do DM ainda n&#227;o foi demonstrada. O objetivo do presente trabalho foi descrever a associa&#231;&#227;o da varia&#231;&#227;o do cronotropismo com doen&#231;a microvascular em pacientes com DM1. </p>
    <p>
      <bold>Metodologia</bold>
    </p>
    <p>Realizamos um estudo transversal com pacientes com DM1, os quais foram selecionados de uma coorte com mais de 300 pacientes acompanhados ambulatorialmente no Hospital de Cl&#237;nicas de Porto Alegre<sup>16</sup>. O Comit&#234; de &#201;tica em pesquisa do hospital (projeto 08-470) aprovou previamente a pesquisa e todos os pacientes, antes de participarem neste estudo, assinaram termo de consentimento livre e esclarecido. Todos os pacientes selecionados haviam realizado TE como estabelecido no protocolo de pesquisa, e, como crit&#233;rio de inclus&#227;o, foi exigido que os pacientes n&#227;o demonstrassem presen&#231;a de isquemia mioc&#225;rdica ou arritmias card&#237;acas durante o exame. Esse crit&#233;rio foi utilizado porque os pacientes com isquemia mioc&#225;rdica estavam em uso de medica&#231;&#245;es com interfer&#234;ncia na frequ&#234;ncia card&#237;aca e por terem limita&#231;&#227;o no esfor&#231;o f&#237;sico m&#225;ximo. Para o indiv&#237;duo ser considerado eleg&#237;vel, ele deveria tamb&#233;m ter teste de sensibilidade perif&#233;rica (monofilamento) normal e n&#227;o ter sintomas de neuropatia auton&#244;mica ou hipotens&#227;o postural durante a avalia&#231;&#227;o cl&#237;nica. Atrav&#233;s de tais crit&#233;rios, foi obtida-se uma amostra composta por 84 pacientes. </p>
    <p>As vari&#225;veis demogr&#225;ficas e antropom&#233;tricas desse grupo foram obtidas atrav&#233;s de entrevista e exame cl&#237;nico. Os pacientes foram tamb&#233;m avaliados quanto &#224; presen&#231;a de nefropatia diab&#233;tica (ND) e retinopatia diab&#233;tica (RD). A presen&#231;a de RD foi avaliada por oftalmoscopia ap&#243;s midr&#237;ase realizada por um mesmo oftalmologista. Os pacientes com qualquer grau de retinopatia durante o exame foram classificados como positivos para a presen&#231;a desta vari&#225;vel. Os pacientes foram categorizados como presen&#231;a de nefropatia atrav&#233;s da an&#225;lise de urina de amostra ou de urina em 24 horas, sendo considerados com nefropatia aqueles com excre&#231;&#227;o urin&#225;ria de albumina superior a 17 mg/dl em amostra ou superior a 20 &#181;g/min em urina de 24 horas<sup>15</sup>, confirmada em pelo duas amostras com intervalo de 06 meses. </p>
    <p>O TE foi realizado de acordo com protocolo de Bruce<sup>16</sup>. Informa&#231;&#245;es sobre sintomas, ritmo, FC e press&#227;o arterial foram coletados no basal e durante os est&#225;gios do protocolo: exerc&#237;cio m&#225;ximo, 1, 2 e 4 minutos ap&#243;s o t&#233;rmino do exame. A carga de trabalho foi avaliada pelo n&#250;mero de equivalentes metab&#243;licos obtidos (METs), definidos em tabelas padronizadas e correspondentes a 3,5 ml de obten&#231;&#227;o de oxig&#234;nio por quilo de peso por minuto<sup>17</sup>. O aumento da FC foi definido como a diferen&#231;a entre a FC do exerc&#237;cio m&#225;ximo e do repouso basal (&#916;FC pico). A FC de recupera&#231;&#227;o foi definida como a diferen&#231;a entre o pico do exerc&#237;cio m&#225;ximo e a FC das fases de recupera&#231;&#227;o com 1, 2 e 4 minutos ap&#243;s o t&#233;rmino do exame (&#916;FC recupera&#231;&#227;o 1, 2 e 4 minutos). Da mesma maneira, pode-se calcular o aumento da press&#227;o arterial sist&#243;lica e diast&#243;lica at&#233; o pico de exerc&#237;cio e a recupera&#231;&#227;o da PA em 1, 2 e 4 minutos ap&#243;s o final do esfor&#231;o (&#916;PAS pico, recupera&#231;&#227;o 1, 2 e 4 minutos; &#916;PAD pico, recupera&#231;&#227;o 1, 2 e 4 minutos). </p>
    <p>A excre&#231;&#227;o urin&#225;ria de albumina (EUA) foi medida em amostras casuais ou em coletas de 24 horas por imunoturbidimetria (MicroAlb Sera-Pak<sup>&#174;</sup> imuno microalbuminuria, Roche<sup>&#174;</sup>, USA) em pelo duas medidas com intervalo de 06 meses<sup>18</sup>. A hemoglobina glicosilada (HbA1c) foi medida por cromatografia l&#237;quida de alta performance (valores de refer&#234;ncia entre 4,7 e 6,0%; Merck-Hitachi 9100, Alemanha). A glicemia de jejum foi medida pelo m&#233;todo da colorim&#233;trico enzim&#225;tico da glicose-peroxidase (Biodiagn&#243;stica, Brasil). A creatinina s&#233;rica foi medida pelo m&#233;todo de Jaff&#233; e o colesterol total e triglicer&#237;deos s&#233;ricos foram medidos por m&#233;todos colorim&#233;tricos enzim&#225;ticos (Merck Diagn&#243;stica, Boeringher Manheim, Alemanha). Para medida do colesterol HDL, foi utilizado m&#233;todo homog&#234;neo direto (<italic>autoanalyzer</italic>, ADVIA 1650, Siemens <italic>Healthcare Diagnostics</italic>, Alemanha). O colesterol LDL foi calculado pela f&#243;rmula de Friedwald<sup>19</sup>. </p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Para an&#225;lise das vari&#225;veis cl&#237;nicas e laboratoriais, foram utilizados os testes <italic>t</italic> de <italic>student</italic> para as vari&#225;veis quantitativas (apresentadas em m&#233;dia &#177; desvio-padr&#227;o) e o qui-quadrado para as qualitativas (apresentadas em percentual do total da amostra). Vari&#225;veis quantitativas sem distribui&#231;&#227;o normal foram log transformadas e s&#227;o apresentadas em mediana e valor m&#237;nimo-m&#225;ximo. An&#225;lises multivariadas foram realizadas com as vari&#225;veis de varia&#231;&#227;o da FC como vari&#225;veis independentes e a presen&#231;a de retinopatia ou nefropatia como vari&#225;veis dependentes. As compara&#231;&#245;es foram ajustadas para m&#250;ltiplos poss&#237;veis fatores de confus&#227;o. Valores <italic>p </italic>inferiores a 0,05 foram considerados estatisticamente significativos. </p>
    <p>
      <bold>Resultado</bold>
    </p>
    <p>A amostra foi composta por 84 pacientes com DM1, tr&#234;s pacientes foram exclu&#237;dos ap&#243;s o teste por apresentarem sinais sugestivos de cardiopatia isqu&#234;mica durante o exame. Da amostra, restaram 81 pacientes: 54,3% (n = 44) masculinos, 17,2% (n = 14) eram tabagistas ativos no momento deste estudo e 46,9% (n = 38) tinham o diagn&#243;stico pr&#233;vio de hipertens&#227;o arterial (HAS). Os pacientes tinham em m&#233;dia 17,6 &#177; 11,2 anos de dura&#231;&#227;o da doen&#231;a e idade m&#233;dia de 40,5 &#177; 10,8 anos. Ap&#243;s a investiga&#231;&#227;o para as complica&#231;&#245;es microvasculares do diabete, 54,3% (n = 44) dos pacientes demonstraram ter algum grau de retinopatia e 33,3% (n = 27) deles foram considerados como tendo nefropatia pelo resultado da microalbumin&#250;ria. Dos pacientes com nefropatia, 37,0% (n = 10) tinham excre&#231;&#227;o de albumina na urina em n&#237;veis de macroalbumin&#250;ria. Por outro lado, entre os pacientes com retinopatia, 20 (45,5%) tinham retinopatia n&#227;o proliferativa leve, dois (4,5%) tinham a forma n&#227;o proliferativa moderada, 06 (13,6%) tinham retinopatia n&#227;o proliferativa grave e 16 (36,4%) tinham retinopatia proliferativa. </p>
    <p>Os dados cl&#237;nicos e laboratoriais dos pacientes estratificados pela presen&#231;a de RD est&#227;o exibidos na <xref ref-type="table" rid="tab1">Tabela 1</xref>. Pacientes com presen&#231;a de retinopatia diab&#233;tica apresentavam maior dura&#231;&#227;o do diabete do que aqueles sem RD (11,4 &#177; 7,8 <italic>vs</italic> 23,4 &#177; 11,3 anos; p &lt; 0,01). A preval&#234;ncia do diagn&#243;stico pr&#233;vio de HAS tamb&#233;m foi maior entre os pacientes com RD (28,1% <italic>vs</italic> 59,1%, p = 0,014), al&#233;m de maiores n&#237;veis s&#233;ricos de creatinina e maior EUA. O controle glic&#234;mico, avaliado pela hemoglobina glicosilada, n&#227;o apresentou associa&#231;&#227;o com esta complica&#231;&#227;o (8,15% &#177; 1,9 <italic>vs</italic> 8,7% &#177; 1,7; p = 0,24). N&#227;o houve diferen&#231;a em rela&#231;&#227;o &#224; idade, sexo ou tabagismo. Durante o TE, observou-se que aqueles pacientes que n&#227;o tinham altera&#231;&#245;es na retina atingiram maiores valores de FC (FC m&#225;xima) durante o exerc&#237;cio, al&#233;m de terem tamb&#233;m um aumento maior da FC em resposta ao exerc&#237;cio em rela&#231;&#227;o &#224; FC basal de repouso (&#916;FC pico), quando comparados com aqueles que apresentaram RD. Da mesma maneira, o &#916;FC recupera&#231;&#227;o em dois e 04 minutos tamb&#233;m foi maior naqueles que n&#227;o tinham RD. </p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt01.jpg"/></table-wrap>
    <p>Considerando as medidas da press&#227;o arterial durante o exerc&#237;cio, os pacientes com RD apresentaram valores mais elevados da press&#227;o arterial sist&#243;lica e diast&#243;lica no repouso, e houve tamb&#233;m um incremento maior da press&#227;o sist&#243;lica at&#233; o pico do exerc&#237;cio (&#916;PAS pico). N&#227;o houve diferen&#231;a no n&#250;mero de METs atingidos pelos dois grupos. Os valores referentes ao teste ergom&#233;trico em pacientes com e sem RD encontram-se na <xref ref-type="table" rid="tab1">Tabela 1</xref>. </p>
    <p>Quando estratificamos os pacientes pelos diferentes graus de RD, observamos que pacientes com a forma RD n&#227;o proliferativa (RDNP) leve apresentaram maior &#916;FC pico que aqueles com RDNP moderada; pacientes sem RD apresentaram maior &#916;FC pico que aqueles com RDNP moderada e RD proliferativa. Ainda, pacientes sem RD apresentaram maior FC m&#225;xima, maior &#916;FC 2 min e maior &#916;FC 4 min que aqueles com RD proliferativa. </p>
    <p>Os pacientes com nefropatia diab&#233;tica apresentaram maior dura&#231;&#227;o do DM por ocasi&#227;o do TE que aqueles sem nefropatia (11,4 &#177; 7,8 <italic>vs</italic> 23,4 &#177; 11,3 anos; p &lt; 0,01). Valores mais elevados de triglicer&#237;deos e creatinina tamb&#233;m apresentaram associa&#231;&#227;o com essa complica&#231;&#227;o. A preval&#234;ncia de HAS foi maior naqueles pacientes com nefropatia (34% <italic>vs</italic> 73,1%; p = 0,04), sem que houvesse diferen&#231;a em rela&#231;&#227;o a sexo e tabagismo. Nesta compara&#231;&#227;o, n&#227;o encontramos diferen&#231;a no controle glic&#234;mico nos pacientes com nefropatia (8,15% &#177; 1,9 <italic>vs</italic> 8,7% &#177; 1,7; p = 0,38). Indiv&#237;duos sem ND tamb&#233;m apresentaram maior &#916;FC pico, maior FC m&#225;xima e maior &#916;FC repouso em dois e 04 minutos. Neste caso, encontramos um &#916;PAD repouso em dois e 04 minutos significativamente maior entre os pacientes sem nefropatia, achado este que n&#227;o havia sido observado em rela&#231;&#227;o &#224; retinopatia. Novamente, o n&#250;mero de METs atingido foi muito semelhante entre os grupos (<xref ref-type="table" rid="tab2">Tabela 2</xref>). </p>
    <table-wrap id="tab2">
      <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt02.jpg"/></table-wrap>
    <p>Realizamos uma regress&#227;o log&#237;stica com controle para os poss&#237;veis fatores de confus&#227;o a fim de verificar se os achados da varia&#231;&#227;o do cronotropismo anteriormente associados com RD permaneceriam estatisticamente significativos. Ap&#243;s o controle para presen&#231;a de HAS e tempo de DM, os &#916;FC recupera&#231;&#227;o em dois e 04 minutos, FC m&#225;xima e o &#916;FC pico permaneceram significativamente associados &#224; retinopatia; a &#916;PAS pico perdeu a signific&#226;ncia ap&#243;s esse ajuste (<xref ref-type="table" rid="tab3">Tabela 3</xref>). </p>
    <table-wrap id="tab3">
      <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt03.jpg"/></table-wrap>
    <p>Em rela&#231;&#227;o &#224; ND, a an&#225;lise foi feita tamb&#233;m com controle para presen&#231;a de HAS e dura&#231;&#227;o do DM. Apenas o &#916;FC recupera&#231;&#227;o em dois e 04 minutos apresentou signific&#226;ncia estat&#237;stica nessa an&#225;lise (<xref ref-type="table" rid="tab4">Tabela 4</xref>). </p>
    <table-wrap id="tab4">
      <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt04.jpg"/></table-wrap>
    <p>A diferen&#231;a entre os valores da FC do pico de exerc&#237;cio para o repouso basal mostrou correla&#231;&#227;o negativa com a press&#227;o arterial sist&#243;lica (PAS) diurna e noturna nos 67 pacientes da amostra que realizaram monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) (r = -0,367, p = 0,003; r = -0,412, p = 0,001, respectivamente). Da mesma maneira, a diferen&#231;a entre a FC no pico de exerc&#237;cio e ap&#243;s 04 minutos de recupera&#231;&#227;o tamb&#233;m apresentou correla&#231;&#227;o negativa com a PAS diurna e noturna em tais pacientes (r = - 0, 329, p = 0,009; r = -0,359, p = 0,004, respectivamente). </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Uma resposta cronotr&#243;pica card&#237;aca inadequada &#224; atividade f&#237;sica sugere fortemente disfun&#231;&#227;o vagal<sup>20</sup>. Pacientes com diabete e disautonomia card&#237;aca reconhecidamente t&#234;m uma toler&#226;ncia reduzida ao exerc&#237;cio e menor variabilidade da FC em diversas situa&#231;&#245;es<sup>4</sup>. Kramer e cols. <sup>6</sup> observaram a associa&#231;&#227;o entre baixa resposta da FC ao exerc&#237;cio f&#237;sico com a presen&#231;a de RD em um grupo de pacientes com DM1 e DM2. Nesse mesmo estudo, a variabilidade no TE apresentou correla&#231;&#227;o significativa com a variabilidade da FC em testes padr&#245;es para NAC<sup>6</sup>. Nossos dados confirmaram os achados de Kramer; a presen&#231;a de RD foi associada &#224; menor varia&#231;&#227;o da FC no TE, e adicionalmente encontramos o mesmo achado para a nefropatia. A menor recupera&#231;&#227;o da FC, no segundo e 4&#186; minutos de repouso ap&#243;s o t&#233;rmino do TE, apresentou significativa associa&#231;&#227;o com a presen&#231;a de nefropatia. O fato de o aumento da FC do basal at&#233; o pico de exerc&#237;cio ter demonstrado associa&#231;&#227;o apenas com a retinopatia, e n&#227;o com nefropatia, pode dever-se &#224; maior preval&#234;ncia de retinopatia em nossa amostra de pacientes. </p>
    <p>A associa&#231;&#227;o entre NAC e nefropatia j&#225; foi demonstrada previamente em pacientes com diabete<sup>9-12,20,21</sup>, entretanto, foram utilizados m&#233;todos mais complexos para a detec&#231;&#227;o de neuropatia auton&#244;mica. A presen&#231;a de NAC tamb&#233;m est&#225; relacionada &#224; menor redu&#231;&#227;o da press&#227;o arterial noturna em pacientes com DM1<sup>20,21</sup>. Tal fato nos permite considerar a menor variabilidade press&#243;rica durante o ciclo sono-vig&#237;lia em pacientes com neuropatia auton&#244;mica como um dos poss&#237;veis mecanismos fisiopatog&#234;nicos para a maior preval&#234;ncia de nefropatia nestes indiv&#237;duos. Em nossa amostra, observamos que um menor aumento da FC durante o exerc&#237;cio e uma menor redu&#231;&#227;o da FC ap&#243;s 04 minutos do t&#233;rmino do exerc&#237;cio correlacionaram-se com medidas maiores de PAS durante o dia e a noite naqueles pacientes que realizaram MAPA. Uma an&#225;lise mais detalhada destes achados pode futuramente contribuir para o melhor entendimento da rela&#231;&#227;o entre NAC e complica&#231;&#245;es microvasculares. </p>
    <p>Dentre as limita&#231;&#245;es do nosso estudo, podemos citar o pequeno tamanho da amostra e o delineamento transversal. Essa &#250;ltima impede-nos de estabelecer rela&#231;&#245;es de causa e efeito entre as vari&#225;veis e de conhecer melhor a interfer&#234;ncia de fatores de risco pr&#233;vios sobre os desfechos (p.ex. , controle glic&#234;mico inadequado e complica&#231;&#227;o microvascular). Esperamos corrigir tais limita&#231;&#245;es atrav&#233;s de uma amplia&#231;&#227;o da amostra e da realiza&#231;&#227;o de uma an&#225;lise prospectiva desses pacientes. </p>
    <p>A vantagem da utiliza&#231;&#227;o do TE para avalia&#231;&#227;o de NAC &#233; que se trata de um m&#233;todo diagn&#243;stico frequentemente utilizado para outras finalidades na aten&#231;&#227;o m&#233;dica a pacientes com DM. A observa&#231;&#227;o cuidadosa dos dados fornecidos pelo exame, especialmente a varia&#231;&#227;o da FC, enriquece a avalia&#231;&#227;o do paciente, permitindo suspeitar da presen&#231;a de neuropatia auton&#244;mica e reconhecer pacientes com maior risco para complica&#231;&#245;es microvasculares. Isso pode ampliar as informa&#231;&#245;es clinicamente relevantes obtidas quando o paciente j&#225; realizou o exame, mesmo que este n&#227;o seja realizado especificamente com esta indica&#231;&#227;o. Desta forma, se utilizado corretamente, seria poss&#237;vel reconhecer precocemente as altera&#231;&#245;es auton&#244;micas card&#237;acas, j&#225; que os testes espec&#237;ficos para NAC n&#227;o s&#227;o rotineiramente realizados pela maioria dos m&#233;dicos cl&#237;nicos por sua complexidade de realiza&#231;&#227;o. </p>
    <p>A relev&#226;ncia deste achado evidencia-se n&#227;o apenas pela sintomatologia envolvida com tal condi&#231;&#227;o, mas tamb&#233;m pelo maior risco vascular j&#225; reconhecido nesses pacientes. Assim, aqueles pacientes, nos quais fossem identificadas as altera&#231;&#245;es sugestivas de disfun&#231;&#227;o auton&#244;mica, mesmo que iniciais, deveriam ser mais atentamente investigados para complica&#231;&#245;es microvasculares e ter seus fatores de risco modific&#225;veis, como press&#227;o arterial e controle glic&#234;mico, mais rigidamente controlados. </p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Altera&#231;&#227;o do cronotropismo card&#237;aco avaliado por TE representa manifesta&#231;&#227;o de NAC e est&#225; associada &#224; presen&#231;a de complica&#231;&#245;es microvasculares, mais especificamente RD e ND. Estudos adicionais s&#227;o necess&#225;rios para saber quais s&#227;o os valores de varia&#231;&#227;o da FC que podem indicar risco aumentado para a presen&#231;a ou desenvolvimento dessas complica&#231;&#245;es. </p>
    <p>
      <fn id="endb" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Ticiana da Costa Rodrigues </p>
        <p> Rua Ramiro Barcelos, 2350 - Bom Fim </p>
        <p> 90520-100 - Porto Alegre, RS - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="ticianacr@yahoo.com.br">ticianacr@yahoo.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 17/10/10; revisado recebido em 23/12/10; aceito em 11/01/11. </p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Ko SH, Park SA, Cho JH, Song KH, Yoon KH, Cha BY, et al. Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2008;31(9):1832-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1832</fpage>
          <lpage>6</lpage>
          <issue>9</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ko</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Cha</surname>
              <given-names>BY</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular risk factors and diabetic neuropathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>341</fpage>
          <lpage>50</lpage>
          <issue>4</issue>
          <volume>352</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tesfaye</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chaturvedi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Manes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ionescu-Tirgoviste</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Rolim LC, S&#225; JR, Chacra AR, Dib SA. Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis. Arq Bras Cardiol. 2008;90(4):e24-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>e24</fpage>
          <lpage>31</lpage>
          <issue>4</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rolim</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>S&#225;</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Chacra</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Dib</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-79.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diabetic autonomic neuropathy</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1553</fpage>
          <lpage>79</lpage>
          <issue>5</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vinik</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Maser</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895-901.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1895</fpage>
          <lpage>901</lpage>
          <issue>6</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maser</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Vinik</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Kramer CK, Leit&#227;o CB, Azevedo MJ, Valiatti FB, Rodrigues TC, Canani LH, et al. Diabetic retinopathy is associated with early autonomic dysfunction assessed by exercise-related heart rate changes. Braz J Med Biol Res. 2008;41(12):1110-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diabetic retinopathy is associated with early autonomic dysfunction assessed by exercise-related heart rate changes</article-title>
          <source>Braz J Med Biol Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1110</fpage>
          <lpage>5</lpage>
          <issue>12</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kramer</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Leit&#227;o</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Valiatti</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Canani</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Pecis M, Azevedo MJ, Moraes RS, Ferlin EL, Gross JL. Autonomic dysfunction and urinary albumin excretion rate are associated with an abnormal blood pressure pattern in normotensive normoalbuminuric type 1 diabetic patients. Diabetes Care. 2000;23(7):989-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Autonomic dysfunction and urinary albumin excretion rate are associated with an abnormal blood pressure pattern in normotensive normoalbuminuric type 1 diabetic patients</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>989</fpage>
          <lpage>93</lpage>
          <issue>7</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pecis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Ferlin</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Garcia C, Mayaudon H, Bordier L, Le Berre JP, Dupuy O, Bauduceau B. Modifications of 24-h blood pressure profile associated with reduction of the heart rate variability in type 1 diabetic patients. Arch Mal Coeur Vaiss. 2007;100(8):699-703.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Modifications of 24-h blood pressure profile associated with reduction of the heart rate variability in type 1 diabetic patients</article-title>
          <source>Arch Mal Coeur Vaiss</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>699</fpage>
          <lpage>703</lpage>
          <issue>8</issue>
          <volume>100</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mayaudon</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bordier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Le Berre</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Dupuy</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bauduceau</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Bilal N, Erdogan M, Ozbek M, Cetinkalp S, Karadeniz M, Ozgen AG, et al. Increasing severity of cardiac autonomic neuropathy is associated with increasing prevalence of nephropathy, retinopathy, and peripheral neuropathy in Turkish type 2 diabetics. J Diabetes Complications. 2008;22(3):181-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increasing severity of cardiac autonomic neuropathy is associated with increasing prevalence of nephropathy, retinopathy, and peripheral neuropathy in Turkish type 2 diabetics</article-title>
          <source>J Diabetes Complications</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>181</fpage>
          <lpage>5</lpage>
          <issue>3</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bilal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Erdogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozbek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cetinkalp</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Karadeniz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozgen</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Chen HT, Lin HD, Won JG, Lee CH, Wu SC, Lin JD, et al. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabetes Res Clin Pract. 2008;82(2):282-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes</article-title>
          <source>Diabetes Res Clin Pract</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>282</fpage>
          <lpage>90</lpage>
          <issue>2</issue>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Won</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Fors&#233;n A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, et al. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. Diabet Med. 2004;21(8):852-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy</article-title>
          <source>Diabet Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>852</fpage>
          <lpage>8</lpage>
          <issue>8</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fors&#233;n</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kangro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sterner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Norrgren</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Thorsson</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Wollmer</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Maguire AM, Craig ME, Craighead A, Chan AK, Cusumano JM, Hing SJ, et al. Autonomic nerve testing predicts the development of complications: a 12-year follow-up study. Diabetes Care. 2007;30(1):77-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Autonomic nerve testing predicts the development of complications: a 12-year follow-up study</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>77</fpage>
          <lpage>82</lpage>
          <issue>1</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maguire</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Craighead</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Cusumano</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hing</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29(2):334-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>334</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Astrup</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Tarnow</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rossing</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>BV</given-names>
            </name>
            <name>
              <surname>Hilsted</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Parving</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Leeper NJ, Dewey FE, Ashley EA, Sandri M, Tan SY, Hadley D, et al. Prognostic value of heart rate increase at onset of exercise testing. Circulation. 2007;115(4):468-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of heart rate increase at onset of exercise testing</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>468</fpage>
          <lpage>74</lpage>
          <issue>4</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Leeper</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Dewey</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Ashley</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Sandri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Hadley</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Shetler K, Marcus R, Froelicher VF, Vora S, Kalisetti D, Prakash M, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol. 2001;38(7):1980-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart rate recovery: validation and methodologic issues</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1980</fpage>
          <lpage>7</lpage>
          <issue>7</issue>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shetler</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Vora</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalisetti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Rodrigues TC, Pecis M, Canani LH, Schreiner L, Kramer CK, Biavatti K, et al. Characterization of patients with type 1 diabetes mellitus in southern Brazil: chronic complications and associated factors. Rev Assoc Med Bras. 2010;56(1):67-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Characterization of patients with type 1 diabetes mellitus in southern Brazil: chronic complications and associated factors</article-title>
          <source>Rev Assoc Med Bras</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <issue>1</issue>
          <volume>56</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Pecis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Canani</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Biavatti</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Fletcher GF, Balady G, Froelicher VF, Haartley LH, Haskell WL, Pollock ML. Exercise standards: a statement for health acre professionals from the American Heart Association. Writing Group. Circulation. 1995;91(2):580-615.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise standards: a statement for health acre professionals from the American Heart Association. Writing Group</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>580</fpage>
          <lpage>615</lpage>
          <issue>2</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fletcher</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Haartley</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Haskell</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28(1):164-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diabetic nephropathy: diagnosis, prevention, and treatment</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>164</fpage>
          <lpage>76</lpage>
          <issue>1</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gross</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>de Azevedo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Silveiro</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Canani</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Caramori</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Zelmanovitz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge</article-title>
          <source>Clin Chem</source>
          <date>
            <year>1972</year>
          </date>
          <fpage>499</fpage>
          <lpage>502</lpage>
          <issue>6</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Friedewald</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Fredrickson</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Monteagudo PT, N&#243;brega JC, Cezarini PR, Ferreira SR, Kohlmann O Jr, Ribeiro AB, et al. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. Eur J Endocrinol. 1996;135(6):683-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients</article-title>
          <source>Eur J Endocrinol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>683</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>135</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Monteagudo</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>N&#243;brega</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Cezarini</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Kohlmann Jr</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care. 1994;17(6):578-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>578</fpage>
          <lpage>84</lpage>
          <issue>6</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spallone</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gambardella</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Maiello</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Barini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Frontoni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Menzinger</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Complicaciones microvasculares y disfunci&#243;n auton&#243;mica card&#237;aca en pacientes con diabetes mellittus tipo 1</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>BACKGROUND: LA presencia de neuropat&#237;a auton&#243;mica card&#237;aca (NAC) en pacientes con diabetes mellittus (DM) est&#225; asociada a aumento de la mortalidad y a complicaciones cr&#243;nicas microvasculares de diabetes. OBJECTIVE: Investigar una posible asociaci&#243;n entre hallazgos sugestivos de NAC durante la realizaci&#243;n de la prueba ergom&#233;trica (PE) y nefropat&#237;a y retinopat&#237;a en pacientes con DM tipo 1. METHODS: Realizamos un estudio transversal con 84 pacientes con DM tipo 1. Todos los pacientes fueron sometidos a evaluaci&#243;n cl&#237;nica y laboratorial y llevaron a cabo PE, siendo que aquellos que presentaron hallazgos sugestivos de isquemia mioc&#225;rdica fueron excluidos del an&#225;lisis de los datos (n = 3). La evaluaci&#243;n de complicaciones microvasculares (retinopat&#237;a y nefropat&#237;a) se realiz&#243; en la muestra. RESULTS: Los pacientes con nefropat&#237;a y aquellos con retinopat&#237;a alcanzaron una frecuencia card&#237;aca (FC) durante el nivel m&#225;ximo de ejercicio (FC m&#225;xima) menor y presentaron aumento menor de FC con relaci&#243;n al reposo (&#916;FC pico) cuando comparados con aquellos sin estas complicaciones. Estos pacientes tambi&#233;n presentaron una menor reducci&#243;n de la FC en el segundo y 4&#186; minutos tras el final de la prueba (&#916;FC recuperaci&#243;n 2 y 4 minutos). Tras la realizaci&#243;n de an&#225;lisis multivariado con control para los posibles factores de confusi&#243;n, los &#916;FC recuperaci&#243;n en dos y 4 minutos, FC m&#225;xima y el &#916;FC pico permanecieron significativamente asociados a la retinopat&#237;a; y los &#916;FC recuperaci&#243;n en el segundo y 4&#186; minutos permanecieron asociados a la presencia de nefropat&#237;a. CONCLUSION: Se puede considerar la PE como un instrumento adicional para la detecci&#243;n precoz de NAC y para identificar pacientes en un mayor riesgo para complicaciones microvasculares de la diabetes.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Diabetes mellitus tipo 1</kwd>
        <kwd>neuropat&#237;as diab&#233;ticas</kwd>
        <kwd>angiopat&#237;as diab&#233;ticas</kwd>
        <kwd>prueba de esfuerzo</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="ab-body2">
          <label>
            <bold>Complicaciones microvasculares y disfunci&#243;n auton&#243;mica card&#237;aca en pacientes con diabetes mellittus tipo 1</bold>
          </label>
          <p>
            <bold>Fernando K. Almeida<sup>I,II</sup>; Jorge L. Gross<sup>I,II</sup>; Ticiana C. Rodrigues<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Servi&#231;o de Endocrinologia do Hospital de Cl&#237;nicas de Porto Alegre</p>
      <p><sup>II</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>BACKGROUND:</bold> LA presencia de neuropat&#237;a auton&#243;mica card&#237;aca (NAC) en pacientes con diabetes mellittus (DM) est&#225; asociada a aumento de la mortalidad y a complicaciones cr&#243;nicas microvasculares de diabetes.</p>
      <p><bold>OBJECTIVE:</bold> Investigar una posible asociaci&#243;n entre hallazgos sugestivos de NAC durante la realizaci&#243;n de la prueba ergom&#233;trica (PE) y nefropat&#237;a y retinopat&#237;a en pacientes con DM tipo 1.</p>
      <p><bold>METHODS:</bold> Realizamos un estudio transversal con 84 pacientes con DM tipo 1. Todos los pacientes fueron sometidos a evaluaci&#243;n cl&#237;nica y laboratorial y llevaron a cabo PE, siendo que aquellos que presentaron hallazgos sugestivos de isquemia mioc&#225;rdica fueron excluidos del an&#225;lisis de los datos (n = 3). La evaluaci&#243;n de complicaciones microvasculares (retinopat&#237;a y nefropat&#237;a) se realiz&#243; en la muestra.</p>
      <p><bold>RESULTS:</bold> Los pacientes con nefropat&#237;a y aquellos con retinopat&#237;a alcanzaron una frecuencia card&#237;aca (FC) durante el nivel m&#225;ximo de ejercicio (FC m&#225;xima) menor y presentaron aumento menor de FC con relaci&#243;n al reposo (&#916;FC pico) cuando comparados con aquellos sin estas complicaciones. Estos pacientes tambi&#233;n presentaron una menor reducci&#243;n de la FC en el segundo y 4&#186; minutos tras el final de la prueba (&#916;FC recuperaci&#243;n 2 y 4 minutos). Tras la realizaci&#243;n de an&#225;lisis multivariado con control para los posibles factores de confusi&#243;n, los &#916;FC recuperaci&#243;n en dos y 4 minutos, FC m&#225;xima y el &#916;FC pico permanecieron significativamente asociados a la retinopat&#237;a; y los &#916;FC recuperaci&#243;n en el segundo y 4&#186; minutos permanecieron asociados a la presencia de nefropat&#237;a.</p>
      <p><bold>CONCLUSION:</bold> Se puede considerar la PE como un instrumento adicional para la detecci&#243;n precoz de NAC y para identificar pacientes en un mayor riesgo para complicaciones microvasculares de la diabetes.</p>
      <p><bold>Keywords:</bold> Diabetes mellitus tipo 1/complicaciones, neuropat&#237;as diab&#233;ticas, angiopat&#237;as diab&#233;ticas, prueba de esfuerzo.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La neuropat&#237;a auton&#243;mica es una complicaci&#243;n cr&#243;nica que resulta de la presencia de la diabetes mellitus (DM) y est&#225; asociada a un control glic&#233;mico inadecuado<sup>1-3</sup>. Sin embargo, a pesar de su elevada prevalencia y del significativo impacto que sus s&#237;ntomas conllevan sobre la calidad de vida de los individuos afectados, ella sigue siendo subdiagnosticada. La gran variedad de manifestaciones cl&#237;nicas y la complejidad de los m&#233;todos de evaluaci&#243;n contribuyen a la poca identificaci&#243;n de los pobres de la neuropat&#237;a auton&#243;mica. Adem&#225;s, se demostr&#243; que su presencia aumenta el riesgo de eventos cardiovasculares y la mortalidad en pacientes con DM<sup>3,4</sup>. La neuropat&#237;a auton&#243;mica card&#237;aca (NAC) tiene una estrecha asociaci&#243;n con mortalidad de origen cardiovascular<sup>4,5</sup> y, m&#225;s recientemente, las evidencias han indicado una asociaci&#243;n entre NAC y complicaciones microvasculares, posiblemente relacionadas a una alteraci&#243;n del control vasomotor de los peque&#241;os vasos<sup>6</sup>. Con relaci&#243;n a NAC, hay diversos m&#233;todos de evaluaci&#243;n bien validados, muchos de ellos disponibles en el consultorio, como la respuesta auton&#243;mica al ortostatismo postural, la maniobra de Valsalva y la variaci&#243;n de la frecuencia card&#237;aca (FC) durante los ciclos de inspiraci&#243;n profunda<sup>4</sup> .</p>
      <p>Entre las manifestaciones t&#237;picas de la neuropat&#237;a auton&#243;mica se incluyen: p&#233;rdida de la percepci&#243;n de hipoglucemias, alteraciones gastrointestinales (diarrea, estre&#241;imiento, incontinencia fecal y gastroparesia), alteraciones urinarios (vejiga neurog&#233;nica, incontinencia como se manifiesta por la retenci&#243;n de orina), disfunciones sexuales, alteraciones de las gl&#225;ndulas sudor&#237;paras (piel seca) y las enfermedades cardiovasculares. Las alteraciones auton&#243;micas cardiovasculares se reflejan m&#225;s precozmente en una reducci&#243;n de la variabilidad de la FC, un fen&#243;meno que, un fen&#243;meno que predispone a la hipotensi&#243;n postural, la intolerancia al ejercicio y la inestabilidad cardiovascular transoperatoria y la taquicardia en reposo<sup>4</sup>. Hay, a la vez, una menor reducci&#243;n en los niveles de la presi&#243;n arterial diast&#243;lica nocturna, fen&#243;meno que podr&#237;a estar implicado tambi&#233;n en el desarrollo de lesiones de &#243;rganos-blanco<sup>7,8</sup>. La frecuencia de NAC aumenta con el avance la edad y con el tiempo de duraci&#243;n del diabetes, y su presencia se asocian con retinopat&#237;a, nefropat&#237;a y neuropat&#237;a perif&#233;rica<sup>3,4,9,10</sup>.</p>
      <p>En los pacientes con diabetes tipo 1 (DM1), las alteraciones cardiacas auton&#243;micas, seg&#250;n lo determinado por el &#237;ndice de la FC en la inspiraci&#243;n/expiraci&#243;n y por la respuesta cardiaca durante la inducci&#243;n de ortostatismo, se relacionaron con el desarrollo de la nefropat&#237;a diab&#233;tica (ND) a lo largo de los a&#241;os<sup>11</sup>. Tambi&#233;n ya se demostr&#243; que trastornos auton&#243;micos detectados por pupilometr&#237;a aumentan el riesgo de enfermedad renal futura<sup>12</sup>. Pacientes con nefropat&#237;a y variaci&#243;n anormal de la FC durante el ciclo de inspiraci&#243;n/expiraci&#243;n presentan un riesgo de eventos cardiovasculares fatal y no fatal mayor que aquellos solamente con nefropat&#237;a y sin los trastornos auton&#243;micos<sup>13</sup>.</p>
      <p>La variaci&#243;n de la FC con relaci&#243;n al nivel pico del ejercicio y a los primeros minutos de recuperaci&#243;n tras la prueba ergom&#233;trica (PE) ya se valid&#243; como factor pron&#243;stico cardiovascular<sup>14,15</sup>. Sin embargo, la asociaci&#243;n de este marcador de disfunci&#243;n auton&#243;mica card&#237;aca con complicaciones de ri&#241;&#243;n del DM no se evidenci&#243; todav&#237;a. El objetivo del presente trabajo ha sido describir la asociaci&#243;n de la variaci&#243;n del cronotropismo con la enfermedad microvascular en pacientes con DM1.</p>
      <p>
        <bold>Metodolog&#237;a</bold>
      </p>
      <p>Realizamos un estudio transversal con pacientes con DM1, los cuales fueron seleccionados de una cohorte con m&#225;s de 300 pacientes seguidos ambulatorialmente en el Hospital de Cl&#237;nicas de Porto Alegre<sup>16</sup>. El Comit&#233; de &#201;tica en investigaci&#243;n del hospital (proyecto 08-329) aprob&#243; previamente la investigaci&#243;n y todos los pacientes, antes de participar en este estudio, firmaron el formulario de consentimiento informado. Todos los pacientes seleccionados se hab&#237;an sometido a la PE seg&#250;n lo establecido en el protocolo de investigaci&#243;n, y como criterio de inclusi&#243;n fue necesario que los pacientes no demostraran la presencia de isquemia de miocardio o arritmias card&#237;acas durante el examen. Este criterio fue utilizado porque los pacientes con isquemia mioc&#225;rdica estaban en uso de medicamentos con la interferencia en la frecuencia cardiaca y han limitado el esfuerzo f&#237;sico m&#225;ximo. Para ser el sujeto considerado elegible, &#233;l deber&#237;a tambi&#233;n tener prueba de sensibilidad perif&#233;rica (monofilamento) normal y no presentar s&#237;ntomas de neuropat&#237;a auton&#243;mica o hipotensi&#243;n postural durante la evaluaci&#243;n cl&#237;nica. Por estos criterios, se obtuvo una muestra conformada de 84 pacientes.</p>
      <p>Las variables demogr&#225;ficas y antropom&#233;tricas en este grupo se obtuvieron mediante entrevista y examen cl&#237;nico. Los pacientes tambi&#233;n fueron evaluados para detectar la presencia de nefropat&#237;a diab&#233;tica (ND) y la retinopat&#237;a diab&#233;tica (RD). La presencia de la RD se evalu&#243; por oftalmoscopia despu&#233;s de midriasis realizada por un mismo oftalm&#243;logo. Los pacientes con alg&#250;n grado de retinopat&#237;a durante el examen fueron clasificados como positivos para la presencia de esta variable. Los pacientes fueron clasificados como presencia de nefropat&#237;a por el an&#225;lisis de orina o muestra de orina en 24 horas, se consideraron aquellos con nefropat&#237;a los con la excreci&#243;n urinaria de alb&#250;mina superior a 17 mg/dl en la muestra o superior a 20 g/min en la orina de 24 horas<sup>15</sup>, confirmada en al menos dos muestras con intervalo de 06 meses. </p>
      <p>La prueba se realiz&#243; seg&#250;n el protocolo Bruce<sup>16</sup>. Informaciones sobre los s&#237;ntomas, el ritmo, la FC y la presi&#243;n arterial se recolectaron en el basal y durante los estadios del protocolo: el ejercicio m&#225;ximo, 1, 2 y 4 minutos despu&#233;s del t&#233;rmino del examen. La carga de trabajo se evalu&#243; por el n&#250;mero de equivalentes metab&#243;licos alcanzados (METs), que se define en las tablas estandarizadas y que corresponden a 3,5 ml de la obtenci&#243;n de ox&#237;geno por kilogramo de peso al minuto<sup>17</sup>. El aumento de la FC se defini&#243; como la diferencia entre la FC del ejercicio m&#225;ximo y del reposo basal (&#916;FC pico). La FC de recuperaci&#243;n se defini&#243; como la diferencia entre el nivel pico del ejercicio y la FC de las fases de recuperaci&#243;n con 1, 2 y 4 minutos tras el t&#233;rmino del examen (&#916;FC recuperaci&#243;n 1, 2 y 4 minutos). Del mismo modo, se puede calcular el aumento de la presi&#243;n arterial sist&#243;lica y diast&#243;lica hasta el nivel pico de ejercicio y la recuperaci&#243;n de PA en 1, 2 y 4 minutos despu&#233;s de la finalizaci&#243;n del esfuerzo (&#916;PAS pico, recuperaci&#243;n 1, 2 y 4 minutos; &#916;PAD pico, recuperaci&#243;n 1, 2 y 4 minutos).</p>
      <p>La excreci&#243;n urinaria de alb&#250;mina (EUA) se midi&#243; en muestras casuales o en recolecciones de 24 horas por inmunoturbidimetria (MicroAlb Sera-Pak<sup>&#174;</sup> imuno microalbuminuria, Roche<sup>&#174;</sup>, USA) en por lo menos dos mediciones con intervalos de 06 meses<sup>18</sup>. La hemoglobina glicosilada (HbA1c) se midi&#243; por cromatograf&#237;a l&#237;quida de alta performance (valores de referencia entre 4,7% y 6,0%; Merck-Hitachi 9100, Alemania). La glucemia en ayunas se midi&#243; por el m&#233;todo enzim&#225;tico colorim&#233;trico de la glucosa-peroxidasa (Biodiagnostics, Brasil). La creatinina s&#233;rica se midi&#243; por el m&#233;todo de Jaff&#233; y el colesterol total y los triglic&#233;ridos s&#233;ricos se midieron por m&#233;todos colorim&#233;tricos enzim&#225;ticos (Merck Diagn&#243;stica, Boeringher Manheim, Alemania). Para la medida del colesterol HDL, se utiliz&#243; el m&#233;todo directo homog&#233;neo (<italic>autoanalyzer</italic>, ADVIA 1650, Siemens <italic>Healthcare Diagnostics</italic>, Alemania). El colesterol LDL fue calculado por la f&#243;rmula Friedwald<sup>19</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Para el an&#225;lisis de las variables cl&#237;nicas y de laboratorio se utilizaron las pruebas <italic>t</italic> de <italic>student</italic> para las variables cuantitativas (presentadas como media &#177; desviaci&#243;n est&#225;ndar) y la prueba de chi-cuadrado para variables cualitativas (presentada como porcentaje del total de la muestra). Las variables cuantitativas sin distribuci&#243;n normal fueron log transformadas y se presentan como mediana y valor m&#237;nimo-m&#225;ximo. El an&#225;lisis multivariado se realiz&#243; con las variables de variaci&#243;n de la FC como variables independientes y la presencia de retinopat&#237;a o nefropat&#237;a como las variables dependientes. Las comparaciones m&#250;ltiples se ajustaron por posibles factores de confusi&#243;n. Fueron considerados como estad&#237;sticamente significativos valores de p inferiores a 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>La muestra estuvo constituida por 84 pacientes con DM1, tres pacientes fueron excluidos despu&#233;s de la prueba debido a que hab&#237;a signos sugestivos de cardiopat&#237;a isqu&#233;mica durante el examen. De la muestra, 81 pacientes permanecieron: 54,3% (n = 44) hombres, 17,2% (n = 14) eran fumadores en el momento de este estudio y el 46,9% (n = 38) ten&#237;a el diagn&#243;stico previo de la hipertensi&#243;n arterial (HAS). Los pacientes ten&#237;an un promedio de 17,6 &#177; 11,2 a&#241;os de duraci&#243;n de la enfermedad y la edad media de 40,5 &#177; 10,8 a&#241;os. Despu&#233;s de la investigaci&#243;n de las complicaciones microvasculares de la diabetes, el 54,3% (n = 44) de los pacientes presentaron alg&#250;n grado de retinopat&#237;a y el 33,3% (n = 27) de ellos fueron considerados como portadores de nefropat&#237;a por el resultado de la microalbumin&#250;ria. De los pacientes con nefropat&#237;a, el 37,0% (n = 10) ten&#237;a niveles de excreci&#243;n de alb&#250;mina en orina en niveles de macroalbuminuria. Por otra parte, entre los pacientes con retinopat&#237;a, 20 (45,5%) ten&#237;an retinopat&#237;a no proliferativa leve, dos (4,5%) presentaron la forma no proliferativa moderada, 06 (13,6%) ten&#237;a retinopat&#237;a no proliferativa severa y 16 (36,4%) ten&#237;an retinopat&#237;a proliferativa.</p>
      <p>Los datos cl&#237;nicos y de laboratorio de pacientes estratificados seg&#250;n la presencia de la RD se muestran en la <xref ref-type="table" rid="tab1-body2">Tabla 1</xref>. Pacientes con presencia de retinopat&#237;a diab&#233;tica presentaban una mayor duraci&#243;n del diabetes que aquellos sin RD (11,4 &#177; 7,8 <italic>vs</italic> 23,4 &#177; 11,3 a&#241;os; p &lt; 0,01). La prevalencia del diagn&#243;stico previo de HAS tambi&#233;n fue mayor entre los pacientes con RD (28,1% <italic>vs</italic> 59,1%, p = 0,014), adem&#225;s de mayores niveles s&#233;ricos de creatinina y mayor EUA. El control gluc&#233;mico, evaluado por la hemoglobina glicosilada, no se asoci&#243; con esta complicaci&#243;n (8,15% &#177; 1,9 <italic>vs</italic> 8,7% &#177; 1,7; p = 0,24). No hubo diferencia con relaci&#243;n a la edad, sexo o uso del tabaco. Durante la PE, se observ&#243; que aquellos pacientes que no presentaban alteraciones en la retina alcanzar&#237;an los m&#225;s altos valores de la FC (FC m&#225;x) durante el ejercicio, y tambi&#233;n un mayor aumento de la FC en respuesta al ejercicio en relaci&#243;n con la FC basal en reposo (&#916;FC pico), cuando comparados con aquellos que presentaron RD. Del mismo modo, el &#916;FC recuperaci&#243;n en 2 y 4 minutos fue tambi&#233;n mayor en aquellos que no ten&#237;an RD.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt01-es.jpg"/></table-wrap>
      <p>Teniendo en cuenta que las mediciones de la presi&#243;n arterial durante el ejercicio, los pacientes con RD mostraron mayores valores de presi&#243;n arterial sist&#243;lica y diast&#243;lica en reposo, y tambi&#233;n hubo un mayor aumento en la presi&#243;n sist&#243;lica hasta el nivel pico del ejercicio (&#916;PAS pico). No hubo diferencia en el n&#250;mero de MET alcanzados por los dos grupos. Los valores correspondientes a la prueba ergom&#233;trica en pacientes con y sin RD est&#225;n detallados en la <xref ref-type="table" rid="tab1-body2">Tabla 1</xref>.</p>
      <p>Cuando se estratific&#243; a los pacientes por diversos grados de RD, se observ&#243; que los pacientes con la forma RD no proliferativa (RDNP) leve tuvieron una mayor &#916;FC pico que los con RDNP moderada; los pacientes sin RD mostraron mayor &#916;FC pico que los con RDNP moderada y la RD proliferativa. Por otra parte, los pacientes sin RD tuvieron mayor FC m&#225;xima, mayor &#916;FC 2 min y mayor &#916;FC 4 que aquellos con RD proliferativa.</p>
      <p>Los pacientes con nefropat&#237;a diab&#233;tica tuvieron una mayor duraci&#243;n del DM por ocasi&#243;n de la PE que aquellos sin nefropat&#237;a (11,4 &#177; 7,8 <italic>vs</italic> 23,4 &#177; 11,3 a&#241;os, p &lt; 0,01). Valores m&#225;s elevados de triglic&#233;ridos y creatinina tambi&#233;n presentaron una asociaci&#243;n con esta complicaci&#243;n. La prevalencia de HAS fue mayor en aquellos pacientes con nefropat&#237;a (34% vs 73,1%, p = 0,04), sin diferencias por sexo y uso del tabaco. En esta comparaci&#243;n, no se encontraron diferencias en el control gluc&#233;mico en los pacientes con nefropat&#237;a (8,15% &#177; 1,9 <italic>vs</italic> 8,7% &#177; 1,7; p = 0,38). Sujetos sin ND tambi&#233;n presentaron una mayor &#916;FC pico, mayor FC m&#225;xima y mayor &#916;FC reposo en 2 y 4 minutos. En este caso, se encuentra una &#916;PAD en reposo en 2 y 4 minutos significativamente mayor entre los pacientes sin nefropat&#237;a, un hallazgo que no se hab&#237;a observado con relaci&#243;n a la retinopat&#237;a. Una vez m&#225;s, el n&#250;mero de MET alcanzado ha sido muy semejante entre los grupos (<xref ref-type="table" rid="tab2-body2">Tabla 2</xref>).</p>
      <table-wrap id="tab2-body2">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt02-es.jpg"/></table-wrap>
      <p> Se realiz&#243; una regresi&#243;n log&#237;stica para controlar posibles factores de confusi&#243;n a fin de verificar si los resultados de variaci&#243;n del cronotropismo previamente asociados con la RD se mantendr&#237;an estad&#237;sticamente significativos. Tras el control para la presencia de HAS y tiempo de DM, los &#916;FC recuperaci&#243;n en 2 y 4 minutos, la FC m&#225;xima y el &#916;FC pico siguieron significativamente asociados con la retinopat&#237;a; la &#916;PAS pico perdi&#243; la significancia tras este ajuste (<xref ref-type="table" rid="tab3-body2">Tabla 3</xref>).</p>
      <table-wrap id="tab3-body2">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt03-es.jpg"/></table-wrap>
      <p>En relaci&#243;n con la ND, el an&#225;lisis tambi&#233;n se realiz&#243; con el control para la presencia de HAS y duraci&#243;n del DM. Solamente el &#916;FC recuperaci&#243;n en 2 y 4 minutos present&#243; significancia estad&#237;stica en este an&#225;lisis (<xref ref-type="table" rid="tab4-body2">Tabla 4</xref>).</p>
      <table-wrap id="tab4-body2">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt04-es.jpg"/></table-wrap>
      <p>La diferencia entre los valores de FC del pico de ejercicio para el reposo basal mostr&#243; correlaci&#243;n negativa con la presi&#243;n arterial sist&#243;lica (PAS), durante el d&#237;a y la noche en los 67 pacientes de la muestra que se sometieron al monitoreo ambulatorio de la presi&#243;n arterial (MAPA) (r = -0,367, p = 0,003; r = -0,412, p = 0,001, respectivamente). Del mismo modo, la diferencia entre la FC en el nivel pico y despu&#233;s de 4 minutos de la recuperaci&#243;n tambi&#233;n mostr&#243; correlaci&#243;n negativa con la PAS diurna y nocturna en estos pacientes (r = - 0, 329, p = 0,009, r = -0,359, p = 0,004, respectivamente).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Una respuesta cronotr&#243;pica card&#237;aca inadecuada a la actividad f&#237;sica sugiere fuertemente una disfunci&#243;n vagal<sup>20</sup>. Los pacientes con diabetes y disautonom&#237;a cardiaca tienen reconocidamente una tolerancia reducida al ejercicio y menor variabilidad de la FC en diversas situaciones<sup>4</sup>. Kramer et al<sup>6</sup> observaron la asociaci&#243;n entre una baja respuesta de la FC al ejercicio f&#237;sico con la presencia de RD en un grupo de pacientes con DM1 y DM2. En este mismo estudio, la variabilidad en el PE present&#243; una correlaci&#243;n significativa con la variabilidad de la FC en pruebas est&#225;ndares para NAC<sup>6</sup>. Nuestros datos confirmaron los hallazgos de Kramer; la presencia de RD se asoci&#243; a la menor variaci&#243;n de la FC en la PE, y adicionalmente encontramos el mismo hallazgo para la nefropat&#237;a. La menor recuperaci&#243;n de la FC, en el segundo y 4&#186; minutos de reposo tras el t&#233;rmino del PE, present&#243; una significativa asociaci&#243;n con la presencia de nefropat&#237;a. El hecho de que el aumento de la FC del basal hasta el pico de ejercicio ha demostrado la asociaci&#243;n con retinopat&#237;a, solamente, y no con nefropat&#237;a puede ser debido a la mayor prevalencia de la retinopat&#237;a en nuestra muestra de pacientes.</p>
      <p>La asociaci&#243;n entre NAC y la nefropat&#237;a se ha demostrado previamente en pacientes con diabetes<sup>9-12,20,21</sup>, sin embargo, m&#233;todos m&#225;s complejos se utilizaron para detectar la neuropat&#237;a auton&#243;mica. La presencia de NAC tambi&#233;n est&#225; asociada a la menor reducci&#243;n de la presi&#243;n arterial nocturna en pacientes DM1<sup>20,21</sup>. Tal hecho nos permite considerar la menor variabilidad de presi&#243;n arterial durante el ciclo sue&#241;o-vigilia en pacientes con neuropat&#237;a auton&#243;mica como uno de los posibles mecanismos fisiopatog&#233;nicos para la mayor prevalencia de nefropat&#237;a en estos individuos. En nuestra muestra, se observ&#243; que un menor aumento de la FC durante el ejercicio y una reducci&#243;n menor de la FC despu&#233;s de 4 minutos del t&#233;rmino del ejercicio se correlacion&#243; con mayores mediciones de la PAS durante el d&#237;a y la noche en aquellos pacientes que realizaron MAPA. Un an&#225;lisis m&#225;s detallado de estos hallazgos puede contribuir a una mejor comprensi&#243;n de la relaci&#243;n entre NAC y las complicaciones microvasculares.</p>
      <p>De entre las limitaciones de nuestro estudio, podemos citar el tama&#241;o de la muestra y el dise&#241;o de corte transversal. Este &#250;ltimo nos impide establecer relaciones de causa y efecto entre las variables y de comprender mejor la influencia de los factores de riesgo anteriores sobre los resultados (por ejemplo, el mal control gluc&#233;mico y las complicaciones microvasculares). Esperamos solucionar estas limitaciones a trav&#233;s de una muestra mayor y la realizaci&#243;n de un an&#225;lisis prospectivo de estos pacientes.</p>
      <p>La ventaja de usar la PE para la evaluaci&#243;n de NAC es que es un m&#233;todo diagn&#243;stico que a menudo se utiliza para otros fines en la atenci&#243;n m&#233;dica a los pacientes con DM. La observaci&#243;n cuidadosa de los datos del examen, en especial la variaci&#243;n de la FC, ennoblece la evaluaci&#243;n del paciente, lo que permite sospechar la presencia de neuropat&#237;a auton&#243;mica y reconocer a los pacientes en mayor riesgo de complicaciones microvasculares. Esto puede ampliar las informaciones cl&#237;nicamente relevantes obtenidas cuando los pacientes ya realizaron los ex&#225;menes, aunque estos no se hacen espec&#237;ficamente para esta indicaci&#243;n. Por lo tanto, si se utiliza correctamente, ser&#237;a posible reconocer las primeras alteraciones auton&#243;micas card&#237;acas, ya que las pruebas espec&#237;ficas para NAC no se realizan rutinariamente por la mayor&#237;a de los m&#233;dicos debido a su complejidad de ejecuci&#243;n.</p>
      <p>La relevancia de este hallazgo se pone de manifiesto no s&#243;lo por los s&#237;ntomas involucrados con esta enfermedad, sino tambi&#233;n por un mayor riesgo vascular ya reconocidos en estos pacientes. Por lo tanto, los pacientes en los que se identificaran las alteraciones sugestivas de disfunci&#243;n auton&#243;mica, incluso las iniciales, deber&#237;an ser investigados m&#225;s cuidadosamente para complicaciones microvasculares y tener sus factores de riesgo modificables, como la presi&#243;n arterial y control de la glucemia, m&#225;s bien controlados.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La alteraci&#243;n del cronotropismo cardiaco evaluado por PE representa una manifestaci&#243;n de NAC y est&#225; asociada con la presencia de complicaciones microvasculares, m&#225;s espec&#237;ficamente RD y ND. Se necesitan estudios adicionales para conocer cu&#225;les son los valores de la variaci&#243;n de la FC que pueden indicar un mayor riesgo de la presencia o el desarrollo de estas complicaciones.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>FAPERGS, FIPE y PRONEX financiaron el presente estudio.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo es parte de l&#237;nea de investigaci&#243;n e iniciaci&#243;n cient&#237;fica de Fernando K. Almeida por el Hospital de Cl&#237;nicas de Porto Alegre.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Microvascular complications and cardiac autonomic dysfunction in patients with diabetes mellitus type 1</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The presence of cardiac autonomic neuropathy (CAN) in patients with diabetes mellitus (DM) is associated with increased mortality and chronic microvascular complications of diabetes. OBJECTIVE: To investigate a possible association between specific findings of CAN during exercise testing (ET) and nephropathy and retinopathy in patients with type 1 DM. METHODS: We conducted a cross-sectional study of 84 patients with type 1 DM. All patients underwent clinical laboratory evaluation and performed ET, and those who presented findings suggesting myocardial ischemia were excluded from data analysis (n = 3). The assessment of microvascular complications (retinopathy and nephropathy) was performed in the sample. RESULTS: Patients with nephropathy and those with retinopathy achieved a lower heart rate (HR) at peak exercise (HR max) and smaller increase in HR in relation to rest (Peak &#916;HR) compared with those without these complications. These patients also had a smaller reduction in HR in the second and 4th minutes after the end of the test (&#916;HR recovery 2 and 4 minutes). After performing a multivariate analysis with control for possible confounding factors, the &#916;HR recovery in two and four minutes, maximum HR and Peak &#916;HR remained significantly associated with retinopathy; and &#916;HR recovery in the second and 4th minutes remained associated with the presence of nephropathy. CONCLUSION: The ET can be considered an additional tool for early detection of CAN and to identify patients at increased risk for microvascular complications of diabetes.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Diabetes mellitus, type 1</kwd>
        <kwd>diabetic neuropathies</kwd>
        <kwd>diabetic angiopathies</kwd>
        <kwd>exercise test</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="enda-body3">
          <label>
            <bold>Microvascular complications and cardiac autonomic dysfunction in patients with diabetes mellitus type 1</bold>
          </label>
          <p>
            <bold>Fernando K. Almeida; Jorge L. Gross; Ticiana C. Rodrigues</bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Servi&#231;o de Endocrinologia do Hospital de Cl&#237;nicas de Porto Alegre</p>
      <p><sup>II</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brasil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The presence of cardiac autonomic neuropathy (CAN) in patients with diabetes mellitus (DM) is associated with increased mortality and chronic microvascular complications of diabetes. </p>
      <p><bold>OBJECTIVE:</bold> To investigate a possible association between specific findings of CAN during exercise testing (ET) and nephropathy and retinopathy in patients with type 1 DM. </p>
      <p><bold>METHODS:</bold> We conducted a cross-sectional study of 84 patients with type 1 DM. All patients underwent clinical laboratory evaluation and performed ET, and those who presented findings suggesting myocardial ischemia were excluded from data analysis (n = 3). The assessment of microvascular complications (retinopathy and nephropathy) was performed in the sample. </p>
      <p><bold>RESULTS:</bold> Patients with nephropathy and those with retinopathy achieved a lower heart rate (HR) at peak exercise (HR max) and smaller increase in HR in relation to rest (Peak &#916;HR) compared with those without these complications. These patients also had a smaller reduction in HR in the second and 4<sup>th</sup> minutes after the end of the test (&#916;HR recovery 2 and 4 minutes). After performing a multivariate analysis with control for possible confounding factors, the &#916;HR recovery in two and four minutes, maximum HR and Peak &#916;HR remained significantly associated with retinopathy; and &#916;HR recovery in the second and 4<sup>th</sup> minutes remained associated with the presence of nephropathy. </p>
      <p><bold>CONCLUSION:</bold> The ET can be considered an additional tool for early detection of CAN and to identify patients at increased risk for microvascular complications of diabetes.</p>
      <p><bold>Keywords:</bold> Diabetes mellitus, type 1/complications; diabetic neuropathies; diabetic angiopathies; exercise test. </p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Autonomic neuropathy is a chronic complication arising from the presence of diabetes mellitus (DM) and is associated with improper glycemic control<sup>1-3</sup>. However, despite its high prevalence and significant impact that its symptoms cause on the quality of life of affected individuals, it remains underdiagnosed. The wide variety of clinical manifestations and the complexity of evaluation methods contribute to a poor identification of autonomic neuropathy. Additionally, it was demonstrated that its presence increases the risk of cardiovascular events and mortality in patients with DM<sup>3,4</sup>. Cardiac autonomic neuropathy (CAN) has a close association with mortality from cardiovascular conditions<sup>4,5</sup> and, more recently, evidence has shown an association between CAN and microvascular complications, possibly related to a change in the vasomotor control of small vessels<sup>6</sup>. Regarding the CAN, there are several well-validated assessment methods, many of them available in the doctors' surgery, such as the autonomic response to standing posture, the Valsalva maneuver and the change in heart rate (HR) during cycles of profound inspiration<sup>4</sup>. </p>
      <p>Typical manifestations of autonomic neuropathy include: loss of awareness of hypoglycemia, gastrointestinal disorders (diarrhea, constipation, fecal incontinence and gastroparesis), urinary disorders (neurogenic bladder, manifested by incontinence and urinary retention), sexual dysfunctions, abnormal sweat glands (dry skin) and cardiovascular diseases. The cardiovascular autonomic disorders are reflected in an early reduction of HR variability, a phenomenon that predisposes to postural hypotension, exercise intolerance and cardiovascular instability during surgery, and tachycardia at rest<sup>4</sup>. Concurrently, there is a smaller reduction in the levels of diastolic blood pressure at night, a phenomenon that could also be implicated in the development of target organ damage<sup>7,8</sup>. The frequency of CAN increases with age and with the duration of diabetes, and its presence is associated with retinopathy, nephropathy and peripheral neuropathy<sup>3,4,9,10</sup>. </p>
      <p>In patients with type 1 diabetes (T1DM), cardiac autonomic disorders, as assessed by HR during inspiration and expiration and the cardiac response during induction of standing, related to the development of diabetic nephropathy (DN) over the years<sup>11</sup>. Other studies havereported that autonomic disturbances detected by pupillometry increase the risk of kidney disease in the future<sup>12</sup>. Patients with nephropathy and abnormal variation in HR during the cycle of inspiration and expiration present a risk of fatal and nonfatal cardiovascular events higher than those with only nephropathy and without autonomic disorders<sup>13</sup>. </p>
      <p>HR variation in relation to peak exercise and the first minutes of recovery after exercise testing (ET) has been validated as a prognostic cardiovascular factor<sup>14,15</sup>. However, the association of this marker of cardiac autonomic dysfunction with renal complications of diabetes has not been demonstrated. The purpose of this study was to describe the association of chronotropism variation with microvascular disease in patients with DM1. </p>
      <p>
        <bold>Methodology</bold>
      </p>
      <p>We conducted a cross-sectional study with patients with DM1, which were selected from a cohort of more than 300 patients followed up at Hospital de Cl&#237;nicas de Porto Alegre<sup>16</sup>. The Research Ethics Committee of the Hospital (project 08-470) previously approved the study and all patients, before participating in this study, signed an informed consent. All patients selected had undergone ET as established in the research protocol, and as a criterion for inclusion, patients should not demonstrate the presence of myocardial ischemia or cardiac arrhythmias during the test. This criterion was used because patients with myocardial ischemia were using medications with interference on heart rate and have limited maximum physical exertion. To be eligible, the individuals should also have normal peripheral sensitivity test (monofilament) and have no symptoms of autonomic neuropathy or postural hypotension during the clinical evaluation. Through such criteria, we obtained a sample consisting of 84 patients. </p>
      <p>The demographic and anthropometric variables in this group were obtained by interview and clinical examination. Patients were also evaluated for the presence of diabetic nephropathy (DN) and diabetic retinopathy (DR). The presence of DR was assessed by ophthalmoscopy after mydriasis performed by the same ophthalmologist. Patients with any degree of retinopathy during the test were classified as positive for the presence of this variable. Patients were categorized as the presence of nephropathy through urine sample analysis or 24-hour urine. Those with urinary albumin excretion exceeding 17 mg/dl in the sample or greater than 20 &#181;g/min in the 24-hour urine<sup>15</sup>, confirmed by at least two samples with interval of 06 months, were considered with nephropathy. </p>
      <p>The ET was performed according to Bruce protocol<sup>16</sup>. Information on symptoms, rhythm, heart rate and blood pressure were collected at baseline and during the stages of the protocol: maximal exercise, 1, 2 and 4 minutes after the test. The workload was assessed by the number of metabolic equivalents achieved (METs), defined in standardized tables and corresponding to 3.5 ml of oxygen obtainned per kilogram of body weight per minute<sup>17</sup>. The increase in HR was defined as the difference between the maximum exercise HR and baseline resting (Peak &#916;HR). The recovery HR was defined as the difference between the peak of maximal exercise and HR of recovery phases with 1, 2 and 4 minutes after the test (&#916;HR recovery 1, 2 and 4 minutes). Likewise, we can calculate the increase in systolic and diastolic blood pressure to peak exercise and recovery BP in 1, 2 and 4 minutes after the end of the exertion (&#916;SBP peak, recovery 1, 2 and 4 minutes; &#916;DBP peak, recovery 1, 2 and 4 minutes). </p>
      <p>Urinary albumin excretion (UAE) was measured in casual samples or in 24-hour collections by immunoturbidimetric (MicroAlb Sera-Pak<sup>TM</sup> immuno microalbuminuria, Roche<sup>TM</sup>, USA) in at least two measurements with an interval of 06 months<sup>18</sup>. The glycosylated hemoglobin (HbA1c) was measured by high performance liquid chromatography (reference values between 4.7 and 6.0%; Merck-Hitachi 9100, Germany). Fasting glucose was measured by enzymatic colorimetric method of glucose-peroxidase (Biodiagn&#243;stica, Brazil). Serum creatinine was measured by Jaff&#233; method and serum total cholesterol and triglycerides were measured by enzymatic colorimetric methods (Merck Diagn&#243;stica, Boeringher Manheim, Germany). To measure HDL cholesterol, we used the direct homogeneous method (AutoAnalyzer, ADVIA 1650, Siemens Healthcare Diagnostics, Germany). LDL cholesterol was calculated by the Friedwald formula<sup>19</sup>. </p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>For analysis of clinical and laboratory variables, we used Student t for quantitative variables (presented as mean &#177; standard deviation) and chi-square test for qualitative variables (presented as percentage of total sample). Quantitative variables without normal distribution were transformed log and are presented as median and minimum-maximum value. Multivariate analyses were performed with the variables of change in HR as independent variables and the presence of retinopathy or nephropathy as dependent variables. The comparisons were adjusted for multiple possible confounding factors. We considered p values below 0.05 statistically significant. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The sample consisted of 84 patients with type 1 diabetes, three patients were excluded after the test because they had signs suggestive of ischemic heart disease during the test. Out of the sample, 81 patients remained: 54.3% (n = 44) male, 17.2% (n = 14) were smokers at the time of this study and 46.9% (n = 38) had previously diagnosed hypertension (HTN). The patients had 17.6 &#177; 11.2 years of average duration of the disease and mean age of 40.5 &#177; 10.8 years. After the investigation for microvascular complications of diabetes, 54.3% (n = 44) of patients demonstrated some degree of retinopathy and 33.3% (n = 27) of them were considered as having nephropathy according to the microalbuminuria results. Out of the patients with nephropathy, 37.0% (n = 10) had albumin excretion in urine levels of macroalbuminuria. On the other hand, among patients with retinopathy, 20 (45.5%) had mild nonproliferative retinopathy, two (4.5%) had moderate non-proliferative form, 06 (13.6%) had severe non-proliferative retinopathy and 16 (36.4%) had proliferative retinopathy. </p>
      <p>The clinical and laboratory data of patients stratified by the presence of DR are shown in <xref ref-type="table" rid="tab1-body3">Table 1</xref>. Patients with presence of diabetic retinopathy had longer duration of diabetes than those without DR (11.4 &#177; 7.8 <italic>vs</italic> 23.4 &#177; 11.3 years; p &lt; 0.01). The prevalence of previous diagnosis of hypertension was higher among patients with DR (28.1% vs. 59.1%, p = 0.014), and higher serum creatinine levels and higher UAE. Glycemic control, assessed by glycated hemoglobin, was not associated with this complication (8.15% &#177; 1.9 <italic>vs</italic> 8.7% &#177; 1.7, p = 0.24). There was no difference regarding age, sex or smoking. During the ET, it was observed that those patients who had no retina disorders reached higher values of HR (HR max) during exercise, and also have a higher increase in HR in response to exercise in relation to baseline HR at rest (Peak &#916;HR), compared to those who had DR. Likewise, the &#916;HR recovery in two and 04 minutes was also higher in those who had no DR. </p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt01-en.jpg"/></table-wrap>
      <p>Considering the measures of blood pressure during exercise, patients with DR showed higher values of systolic and diastolic blood pressure at rest, and there was also a greater increase in systolic pressure to peak exercise (&#916;SBP Peak). There was no difference in the number of METs achieved by the two groups. The figures for exercise testing in patients with and without DR are shown in <xref ref-type="table" rid="tab1-body3">Table 1</xref>. </p>
      <p>When we stratified the patients by varying degrees of DR, we observed that patients with light nonproliferative DR (NPDR) had higher Peak &#916;HR than those with moderate NPDR; patients without DR showed higher peak &#916;HR than those with moderate NPDR and proliferative DR. Moreover, patients without DR had a higher maximum HR, higher 2 min &#916;HR and higher 4 min &#916;FC than those with proliferative DR. </p>
      <p>Patients with diabetic nephropathy had higher duration of diabetes mellitus at the time of the ET than those without nephropathy (11.4 &#177; 7.8 <italic>vs</italic> 23.4 &#177; 11.3 years; p &lt; 0.01). Higher values of triglycerides and creatinine were also associated with this complication. The prevalence of hypertension was higher in patients with nephropathy (34% <italic>vs</italic> 73.1%; p = 0.04), without differences by gender and smoking. In this comparison, we found no difference in the glycemic control in patients with nephropathy (8.15 &#177; 1.9% <italic>vs</italic> 8.7% &#177; 1.7, p = 0.38). Individuals without DN also showed higher Peak &#916;HR, maximum HR and higher &#916;FC at rest in two and 04 minutes. In this study, we find a &#916;DBP at rest in two and 04 minutes significantly higher among patients without nephropathy, a finding that had not been observed in relation to retinopathy. Again, the number of METs achieved were very similar between groups (<xref ref-type="table" rid="tab2-body3">Table 2</xref>). </p>
      <table-wrap id="tab2-body3">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt02-en.jpg"/></table-wrap>
      <p>We performed a logistic regression controlling for possible confounding factors in order to confirm whether the findings of chronotropism variation previously associated with diabetic retinopathy would remain statistically significant. After controlling for the presence of hypertension and DM duration, the &#916;HR recovery in two and 04 minutes, maximum &#916;HR and Peak &#916;HR remained significantly associated with retinopathy; peak &#916;SBP lost significance after this adjustment (<xref ref-type="table" rid="tab3-body3">Table 3</xref>). </p>
      <table-wrap id="tab3-body3">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt03-en.jpg"/></table-wrap>
      <p>In relation to the DN, the analysis was also performed controlling for the presence of hypertension and diabetes mellitus duration. Only the &#916;HR recovery in two and 04 minutes was statistically significant in this analysis (<xref ref-type="table" rid="tab4-body3">Table 4</xref>). </p>
      <table-wrap id="tab4-body3">
        <graphic xlink:href="1678-4170-abc-96-06-0484-00047-gt04-en.jpg"/></table-wrap>
      <p>The difference between peak exercise HR values for baseline rest was negatively correlated with diurnal and nocturnal systolic blood pressure (SBP) in the 67 patients in the sample who underwent ambulatory blood pressure monitoring (ABPM) (r =-0.367, p = 0.003; r = -0.412, p = 0.001, respectively). Likewise, the difference between HR at peak exercise and after 04 minutes of recovery also showed a negative correlation with the diurnal and nocturnal SBP in these patients (r = - 0, 329, p = 0.009, r = -0.359, p = 0.004, respectively). </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>An inadequate cardiac chronotropic response to physical activity strongly suggests vagal dysfunction<sup>20</sup>. Patients with diabetes and cardiac dysautonomia admittedly have a reduced exercise tolerance and reduced HR variability in several situations<sup>4</sup>. Kramer et al<sup>6</sup> observed the association between low HR response to physical exercise in the presence of DR in a group of patients with DM1 and DM2. In the same study, the variability in ET showed a significant correlation with HR variability in standard tests for CAN<sup>6</sup>. Our data confirmed the findings of Kramer; the presence of DR was associated with lower HR variation on ET, as well as the same finding for nephropathy. The lower HR recovery in the second and 4<sup>th</sup> minutes of rest after the ET showed a significant association with the presence of nephropathy. The fact that the HR increase from baseline to peak exercise has shown an association with retinopathy only, rather than with nephropathy may be due to the higher prevalence of retinopathy in our sample of patients. </p>
      <p>The association between CAN and nephropathy has been demonstrated previously in patients with diabetes<sup>9-12,20,21</sup>, however, more complex methods were used to detect autonomic neuropathy. The presence of CAN is also associated with smaller nocturnal blood pressure reduction in patients with DM1<sup>20,21</sup>. This fact allows us to consider the slightest pressure variability during sleep-wake cycle in patients with autonomic neuropathy as a possible physiopathological mechanism for the higher prevalence of nephropathy in these individuals. In our sample, we observed that a smaller increase in heart rate during exercise and a smaller reduction in HR after 04 minutes of cessation of exercise correlated with higher measures of SBP during the day and night in those patients who underwent ABPM. A more detailed analysis of these findings may eventually contribute to a better understanding of the relationship between CAN and microvascular complications. </p>
      <p>Among the limitations of our study, we can cite the small sample size and cross-sectional design. The latter prevents us from establishing relationships of cause and effect between variables and to better understand the influence of risk factors on previous outcomes (e.g. , poor glycemic control and microvascular complication). We expect to fix these limitations through a larger sample and conducting a prospective analysis of these patients. </p>
      <p>The advantage of using the ET for evaluation of CAN is that it is a diagnostic method often used for other purposes in medical care to patients with DM. Careful observation of data from the test, especially the variation in HR, enriches the evaluation of the patient, allowing to suspect of the presence of autonomic neuropathy and recognize patients at increased risk for microvascular complications. This can expand the clinically relevant information obtained when patients were tested, even though this is not done specifically for this indication. Thus, if used correctly, it would be possible to recognize early cardiac autonomic changes, since specific tests for CAN are not routinely performed by most clinicians because of its complex implementation. </p>
      <p>The relevance of this finding is evidenced not only by the symptoms involved with this condition, but also by increased vascular risk already recognized in these patients. Thus, those patients in whom the alterations were identified to be suggestive of autonomic dysfunction, even if at an initial stage, should be more closely investigated for microvascular complications and have their modifiable risk factors such as blood pressure and glycemic control, more tightly controlled. </p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Alteration of cardiac chronotropism evaluated by ET is a manifestation of CAN and is associated with the presence of microvascular complications, specifically DR and DN. Additional studies are needed to know what are the values of HR variation that may indicate increased risk for the presence or development of these complications. </p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
